The promising alliance of anti-cancer electrochemotherapy with immunotherapyReport as inadecuate

The promising alliance of anti-cancer electrochemotherapy with immunotherapy - Download this document for free, or read online. Document in PDF available to download.

Cancer and Metastasis Reviews

, Volume 35, Issue 2, pp 165–177

First Online: 18 March 2016DOI: 10.1007-s10555-016-9615-3

Cite this article as: Calvet, C.Y. & Mir, L.M. Cancer Metastasis Rev 2016 35: 165. doi:10.1007-s10555-016-9615-3


Anti-tumor electrochemotherapy, which consists in increasing anti-cancer drug uptake by means of electroporation, is now implanted in about 140 cancer treatment centers in Europe. Its use is supported by the English National Institute for Health and Care Excellence for the palliative treatment of skin metastases, and about 13,000 cancer patients were treated by this technology by the end of 2015. Efforts are now focused on turning this local anti-tumor treatment into a systemic one. Electrogenetherapy, that is the electroporation-mediated transfer of therapeutic genes, is currently under clinical evaluation and has brought excitement to enlarge the anti-cancer armamentarium. Among the promising electrogenetherapy strategies, DNA vaccination and cytokine-based immunotherapy aim at stimulating anti-tumor immunity. We review here the interests and state of development of both electrochemotherapy and electrogenetherapy. We then emphasize the potent beneficial outcome of the combination of electrochemotherapy with immunotherapy, such as immune checkpoint inhibitors or strategies based on electrogenetherapy, to simultaneously achieve excellent local debulking anti-tumor responses and systemic anti-metastatic effects.

KeywordsElectrochemotherapy Electrogenetherapy Immunotherapy Cancer Metastasis Immunity  Download fulltext PDF

Author: Christophe Y. Calvet - Lluis M. Mir


Related documents